ImmuneWalk Therapeutics Reports Positive Phase 1 Results for IW-601, Novel Myeloid Cell Inhibitor for Inflammatory Diseases
Key Insights
ImmuneWalk Therapeutics (search) announced positive results from the POINTGUARD Phase 1 study of IW-601 (search), meeting all primary and secondary endpoints with demonstrated safety and tolerability at all tested doses.
The novel monoclonal antibody targets MOSPD2 (search) protein on myeloid cells, achieving blood concentrations 3-6 fold higher than levels required for >85% inhibition of myeloid cell migration.
IW-601 (search) showed a favorable pharmacokinetic profile with a ~4-week half-life, suggesting potential for monthly subcutaneous dosing after initial loading phase.
ImmuneWalk Therapeutics (search) announced positive results from its first-in-human Phase 1 POINTGUARD study evaluating IW-601 (search), a novel monoclonal antibody targeting myeloid cell infiltration in inflammatory and autoimmune diseases. The study met all primary and secondary endpoints, demonstrating safety, tolerability, and mechanistic validation of the company's innovative approach to addressing inflammation driven by monocytes and neutrophils.
Novel Mechanism Targets Myeloid Cell Trafficking
IW-601 (search) represents a breakthrough in myeloid cell trafficking by targeting MOSPD2 (search), a cell surface protein expressed specifically on myeloid cells. The drug's mechanism involves inhibiting MOSPD2 to keep β2-integrin (search) in a high affinity adherent state on immune cells, blocking pathologic tissue infiltration that drives chronic inflammation while preserving systemic immune function.
"The IW-601 (search) results from the POINTGUARD study have demonstrated an excellent target product profile with applicability for both orphan and highly prevalent I&I indications," said Dror Harats, MD, Chief Executive Officer of ImmuneWalk Therapeutics (search). "These results validate our novel approach to addressing inflammation driven by monocytes and neutrophils, which plays a central role in many auto-inflammatory and auto-immune diseases."
Phase 1 Study Design and Results
The POINTGUARD study was a randomized, double-blind, placebo-controlled, dose-ranging study evaluating subcutaneous administration of IW-601 (search) in healthy subjects aged 18-50. The trial included four single ascending dose (SAD) cohorts and three multiple ascending dose (MAD) cohorts, with doses ranging from 0.5mg/kg to 10mg/kg. Each cohort enrolled 6 treated subjects and 2 placebo subjects.
Safety and tolerability were demonstrated at all doses with no serious adverse events or dose-limiting toxicities observed. The only drug-related adverse events were mild and transient self-resolving injection site reactions. Importantly, there were no clinically relevant changes in safety parameters and clinical laboratory tests, including complete blood count, chemistry, coagulation, immunophenotyping and urinalysis.
Favorable Pharmacokinetic Profile
The pharmacokinetic profile showed dose-proportional increases in plasma concentrations across all cohorts with a long half-life of approximately 4 weeks, suggesting the potential for monthly subcutaneous dosing after an initial dose loading phase. The achieved blood concentrations, Cmax and exposure, were 3-6 fold higher than the levels required for >85% inhibition of myeloid cell migration ex-vivo.
Target engagement was confirmed through specific time- and dose-dependent binding of IW-601 (search) to myeloid cells (monocytes and neutrophils), but not T-lymphocytes, confirming its expected specificity based on its mechanism of action. This selectivity was demonstrated in assays using blood samples from patients with relapsing/remitting and progressive multiple sclerosis (search), Crohn's disease (search), ulcerative colitis (search), arthritis, psoriatic arthritis (search), Behçet's disease (search) and familial Mediterranean fever (search).
Clinical Development Timeline
ImmuneWalk Therapeutics (search) is rapidly preparing to initiate a Phase 2 study in Behçet's disease (search), a neutrophil-driven rare inflammatory disorder selected as the initial proof-of-concept indication, in the second quarter of 2026. This will be followed by a Phase 2b study in a highly prevalent inflammatory and immunology disease in the first half of 2027.
The approach offers potential therapeutic advantages in a broad spectrum of inflammatory and autoimmune diseases characterized by aberrant monocyte and neutrophil infiltration. Robust disease-modifying preclinical activity has been demonstrated with IW-601 (search) in ex-vivo patient samples and in-vivo animal models of multiple sclerosis (search), rheumatoid arthritis (search), inflammatory bowel disease (search), metabolic dysfunction-associated steatohepatitis (search) (MASH), uveitis (search) and Behçet's disease (search).
Differentiated Therapeutic Approach
While current treatments for immune and inflammatory conditions mainly target T-cells and B-cells, many patients either show resistance or experience limited, short-term benefits using these approaches. IW-601 (search)'s novel mechanism offers potential advantages over traditional approaches by overcoming the redundancy of chemotaxis pathways and directly modulating tissue inflammation while preserving systemic immune function.
The company plans to present the complete results at a scientific meeting in 2026, providing additional details on the mechanistic validation and clinical implications of this novel therapeutic approach.